Biweekly Irinotecan and Cisplatin as Second-line Chemotherapy in Pretreated Patients with Advanced Gastric Cancer: A Multicenter Phase II Study
- Author(s)
- Jin Ho Baek; Jong Gwang Kim; Sang Kyun Sohn; Dong Hwan Kim; Kyu Bo Lee; Hong Suk Song; Ki Young Kwon; Young Rok Do; Hun Mo Ryoo; Sung Hwa Bae; Keon Uk Park; Min Kyoung Kim; Kyung Hee Lee; Myung Soo Hyun; Ho Young Chung; Wansik Yu
- Keimyung Author(s)
- Song, Hong Suk; Kwon, Ki Young; Do, Young Rok; Park, Keon Uk
- Department
- Dept. of Internal Medicine (내과학)
- Journal Title
- Journal of Korean Medical Science
- Issued Date
- 2005
- Volume
- 20
- Issue
- 6
- Keyword
- irinotecan; Cisplatin; Drug Therapy; Stomach Neopla는
- Abstract
- The current phase II study was conducted to evaluate the response rate and safety
of a combination regimen of biweekly irinotecan plus cisplatin in pretreated patients
with advanced gastric cancer. Patients with previously treated metastatic or recurrent
gastric cancer received intravenous irinotecan 70 mg/m2 and cisplatin 30
mg/m2 on day 1 and 15 every 4-week cycle. Thirty-two patients were enrolled in the
current study. Of these, 31 patients were assessable for efficacy and all for toxicity.
No complete response and 5 partial responses were confirmed, giving an overall
response rate of 15.6% (95% CI; 2.3-28.9%). The median time to progression and
median overall survival for all patients was 113 days and 184 days, respectively.
Grade 3/4 neutropenia occurred in 6 patients (18.8%), yet no febrile neutropenia
was observed. In addition, grade 3 anorexia was observed in 4 patients (12.5%)
and grade 3 diarrhea occurred in 2 patients (6.2%). The combination chemotherapy
of biweekly irinotecan and cisplatin was found to be moderately effective and well
tolerated in pretreated patients with advanced gastric cancer. Accordingly, this regimen
can be regarded as an important second-line treatment option for advanced
gastric cancer.
- Authorize & License
-
- Files in This Item:
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.